Bently P Doonan, MD - Research

Research at a glance

Top areas of exploration

Antigen Presentation , 4 publications
Melanoma , 3 publications
Autophagy , 3 publications
CD4-Positive T-Lymphocytes , 3 publications

Research activity

16 publications

269 citations

Why is this important?

Active clinical trials

Oral IRAK-4 inhibitor CA-4948 in combination with Pembrolizumab following stereotactic radiosurgery

This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic radiosurgery in patients with melanoma brain metastases (MBM). The investigators hypothesize…

Investigator: Bently P Doonan
Status: Accepting Candidates
Ages: 18 Years - 99 Years
Sexes: All

Pembro With Investigational Agents or Pembro Alone in First Line (1L) Advanced Melanoma

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02B is to evaluate the safety and efficacy of investigational…

Investigator: Bently P Doonan
Status: Accepting Candidates
Ages: 18 Years - 120 Years
Sexes: All

My publications

16 publications

2024

mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.

Genome medicine

PubMed • Publisher's site

2024

The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations

World Neurosurgery

Publisher's site

2023

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade.

Research square

PubMed • Publisher's site

2023

Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors.

Oncology (Williston Park, N.Y.)

PubMed • Publisher's site

2023

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

Clinical Cancer Research

Publisher's site

My Location

Bently P Doonan, MD : Research

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.

The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade.

Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors.

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

Provide website feedback?

Site Feedback

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Filter publications

mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.

The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade.

Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors.

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

Provide website feedback?

Site Feedback